(PharmaNewsWire.Com, July 22, 2017 ) The global bioreactors market is expected to reach to USD 1,417 Million by 2021 from USD 955 Million in 2015, at a CAGR of 6.8% between 2015 and 2021. The increase in adoption of single-use technologies, use of hybrid technologies: single-use and stainless steel, growing popularity of single-use bioreactor among biopharmaceutical companies, and growing biologics are spurring the growth of the bioreactors market. However, regulatory concerns related to single-use bioreactors, issues regarding leachable and extractable related to single-use bags is hampering the growth of this market.
The global bioreactor market is segmented on the basis of end-users, usage, scale, material, control types and suppliers. Furthermore, the geographic analysis covers North America, Europe, Asia-Pacific, and Rest of the World (RoW).
On the basis of end-user, the bioreactor market has been segmented into R&D departments and biopharmaceutical manufacturers. The R&D departments segment is expected to register the highest growth rate from 2016 to 2021 owing to increased bioreactor usage in process development. Contract manufacturing organizations (CMOs) on the other hand are expected to gain traction in the coming years due to rise in outsourcing needs for biologics manufacturers as a result of increased demand of biologics.
By material, single-use bioreactors are expected to register second highest growth by volume during the forecast period from 2016 to 2021. High growth in this segment is attributed to the advantages of SUBs such as reduced need for cleaning and sterilization, reduced risk of cross contamination, and greater control over aseptic conditions.
Bioreactors are mainly used for growing organisms such as bacteria or yeast that are used in the biotechnological production of substances such as pharmaceuticals, antibodies, and vaccines or for bioconversion of organic waste. By usage, it is segmented into lab-scale, pilot-scale and full-scale production. The lab-scale production segment will witness maximum growth by volume from 2016 to 2021, owing to process development in R&D departments.
By control type, the bioreactor market is segmented into manual and automated control type. In 2015, in terms of volume, the automated control type segment accounted for the largest share of the bioreactors market. In the present scenario, the preference for mass flow controllers (MFCs) is growing, resulting into usage of automated control type. This is because they add additional security assurance and reduce the operating costs of bioreactors. Running bioreactors on MFCs does not require skilled labour. As a result, an increasing number of companies are opting for MFCs.
By suppliers, the market is segmented into Original Equipment Manufacturers (OEMs), system integrators and Engineering Procurement and Construction (EPCs). OEMs not only supply the equipment but also set up the piping and integration, instrumentation, programing, and control. In 2015, OEMs accounted for the larger market share compared to EPCs.
The North American region accounted for the largest share in the bioreactors market in 2016. One of the main factors contributing to this large share is the increase in number of biomanufacturing facilities and investments in this region. Government in North American countries actively supports the biologics production by providing funds to life science R&D.
The bioreactors market is a competitive market with a large number of companies operational in the market. The competitive landscape includes an in-depth market share analysis along with the key business strengths of leading players in the market. Some of the leading players offering bioreactor products are Sartorius AG (Germany), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), GE Healthcare (A subsidiary of General Electric Company) (U.S.), Danaher Corporation (U.S), Eppendorf AG (Germany).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
